Orally-Delivered, Cytokine-Engineered Extracellular Vesicles for Targeted Treatment of Inflammatory Bowel Disease

In a murine model of colitis, Gal-IL10-extracellular vesicles alleviated inflammatory bowel disease symptoms including inflammatory responses and disrupted colonic barriers.